<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04035434</url>
  </required_header>
  <id_info>
    <org_study_id>CRSP-ONC-001</org_study_id>
    <nct_id>NCT04035434</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies</brief_title>
  <official_title>A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CRISPR Therapeutics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CRISPR Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and
      efficacy of CTX110 in subjects with relapsed or refractory B-cell malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study may enroll up to 95 subjects in total.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Anticipated">August 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2026</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 (Dose Escalation): Incidence of adverse events, defined as dose-limiting toxicities</measure>
    <time_frame>From CTX110 infusion up to 28 days post-infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 (Cohort Expansion): Objective response rate</measure>
    <time_frame>From CTX110 infusion up to 60 months post-infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>From date of first objective response of CR/PR until date of disease progression or death due to any cause, assessed up to 60 months</time_frame>
    <description>Duration of Response (DOR) will only be reported for subjects who have had CR/PR events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From date of CTX110 infusion until date of disease progression or death due to any cause, assessed up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of CTX110 infusion until date of death due to any cause, assessed up to 60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">95</enrollment>
  <condition>B-cell Malignancy</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>CTX110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered by IV infusion following lymphodepleting chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CTX110</intervention_name>
    <description>CTX110 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components</description>
    <arm_group_label>CTX110</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Age ≥18 years.

          2. Refractory or relapsed non-Hodgkin lymphoma, as evidenced by 2 or more lines of prior
             therapy.

          3. Eastern Cooperative Oncology Group performance status 0 or 1.

          4. Adequate renal, liver, cardiac and pulmonary organ function

          5. Female subjects of childbearing potential and male subjects must agree to use
             acceptable method(s) of contraception from enrollment through at least 12 months after
             CTX110 infusion.

          6. Agree to participate in an additional long-term follow-up study after completion of
             this study.

        Key Exclusion Criteria:

          1. Treatment with any gene therapy or genetically modified cell therapy, including CAR T
             cells.

          2. Prior allogeneic HSCT.

          3. History of central nervous system (CNS) involvement by malignancy

          4. History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia,
             cerebellar disease, or any autoimmune disease with CNS involvement.

          5. Presence of bacterial, viral, or fungal infection that is uncontrolled or requires IV
             anti-infectives.

          6. Active HIV, hepatitis B virus or hepatitis C virus infection.

          7. Previous or concurrent malignancy, except basal cell or squamous cell skin carcinoma,
             adequately resected and in situ carcinoma of cervix, or a previous malignancy that was
             completely resected and has been in remission for ≥5 years.

          8. Use of systemic anti-tumor therapy or investigational agent within 14 days or 5
             half-lives, whichever is longer, of enrollment.

          9. Primary immunodeficiency disorder or active autoimmune disease requiring steroids
             and/or other immunosuppressive therapy.

         10. Women who are pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ewelina Morawa, MD</last_name>
    <role>Study Director</role>
    <affiliation>CRISPR Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials</last_name>
    <phone>+1 (877) 214-4634</phone>
    <email>MedicalAffairs@crisprtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph P McGuirk, DO</last_name>
      <phone>913-708-4032</phone>
      <email>jmcguirk@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Richard Dugan-Starr</last_name>
      <email>rduganstarr@kumc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Maziarz, MD</last_name>
      <email>maziarzr@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kevin Christmas, PhD</last_name>
      <phone>503-494-6474</phone>
      <email>christmk@ohsu.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Ho, MBBS</last_name>
      <phone>+61 2 95158036</phone>
      <email>christine.contacos@health.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Christine Contacos, PhD</last_name>
      <phone>+61 2 95153370</phone>
      <email>christine.contacos@health.nsw.gov.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Constantine Tam, MBBS, MD</last_name>
      <phone>+61 3 8559 7858</phone>
      <email>constantine.tam@petermac.org</email>
    </contact>
    <contact_backup>
      <last_name>Michael Dickinson, MBBS, MD</last_name>
      <phone>+61 3 8559 7858</phone>
      <email>michael.dickinson@petermac.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20148</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natascha von Huenerbein</last_name>
      <phone>+49 (0) 40 7410-23181</phone>
      <email>n.von-huenerbein@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Marion Heinzelmann</last_name>
      <phone>+49 (0) 40 7410 - 54188</phone>
      <email>mheinzel@uke.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAR T</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>NHL</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Allogeneic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

